Skip to main content
Publications
Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Shah R, Girard N, Nagar SP, Griesinger F, Roeper J, Davis KL, Karimi P, Sawyer W, Yu N, Taylor A, Feliciano J. European and US real-world treatment patterns in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: a retrospective medical record review. Drugs Real World Outcomes. 2021 Dec;8(4):537-45. doi: 10.1007/s40801-021-00261-8
Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegard A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Use of topical tacrolimus and topical pimecrolimus in four European countries: a multicentre database cohort study. Drugs Real World Outcomes. 2018 Jun;5(2):109-16. doi: 10.1007/s40801-018-0133-1
Camilleri M, Lembo AJ, Lavins BJ, Macdougall JE, Carson RT, Williams VSL, Nelson LM, Shiff SJ, Currie MG, Kurtz CB, Johnston JM. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. United European Gastroenterol J. 2015 Feb 3;3(1):53-62. doi: 10.1177/2050640614555946